Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole
Authors:
- 1 January 2001
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 31 (1) , 1-10
Abstract
1. The inhibitory effects of cimetidine, nizatidine and omeprazole on the metabolic activity of CYP2C9, 2C19, 2D6 and 3A were investigated in human liver microsomes. Both cimetidine and omeprazole inhibited each of the CYP subfamily enzymes; in particular, omeprazole extensively inhibited the hydroxylation of S-mephenytoin (CYP2C19, K1 = 7.1 μM). Nizatidine exhibited no inhibition of any of the CYP isoforms examined. 2. Cimetidine inhibited the hydroxylation of tolbutamide but not of diclofenac, whereas omeprazole inhibited the hydroxylation of diclofenac but not that of tolbutamide. The ability to inhibit CYP2C9 varied with incubation time, as measured by the metabolic rate constant for the substrates. Therefore, suitable substrates and incubation times must be selected in inhibition studies examining metabolic clearance and the mechanism of inhibition of these drugs. 3. Nizatidine did not inhibit the metabolism of cisapride, glibenclamide, benidipine and simvastatin. Omeprazole inhibited the metabolism of cisapride (K1 = 0.4 μm), glibenclamide (11.7 μm) and benidipine (6.5 μm), whereas cimetidine inhibited the metabolism of glibenclamide (11.6 μm). To avoid drug-drug interactions, care needs to be taken to select suitable medicines for co-administration with anti-ulcer drugs.Keywords
This publication has 18 references indexed in Scilit:
- Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazoleBritish Journal of Clinical Pharmacology, 1998
- Lack of inhibitory effect of cimetidine on caffeine metabolism in children using the caffeine breath testBritish Journal of Clinical Pharmacology, 1997
- CisaprideDrug Safety, 1996
- In vitrointeraction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3ABritish Journal of Clinical Pharmacology, 1996
- Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation ofin vitrometabolism using cDNA-expressed human P450s and human liver microsomesXenobiotica, 1996
- Gliclazide hydroxylation by rat liver microsomesXenobiotica, 1995
- Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liverLife Sciences, 1993
- Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazoleDigestive Diseases and Sciences, 1991
- Pharmacokinetic and Pharmacodynamic Properties of Histamine H2-Receptor AntagonistsClinical Pharmacokinetics, 1991
- Lack of Effect of Nizatidine on Drug MetabolismScandinavian Journal of Gastroenterology, 1987